Prioritisation of oncology therapeutic targets using CRISPR-Cas9 screening

Citations Over Time

Abstract

Summary Functional genomics approaches can overcome current limitations that hamper oncology drug development such as lack of robust target identification and clinical efficacy. Here we performed genome-scale CRISPR-Cas9 screens in 204 human cancer cell lines from 12 cancer-types and developed a data-driven framework to prioritise cancer therapeutic candidates. We integrated gene cell fitness effects with genomic biomarkers and target tractability for drug development to systematically prioritise new oncology targets in defined tissues and genotypes. Furthermore, we took one of our most promising dependencies, Werner syndrome RecQ helicase, and verified it as a candidate target for tumours with microsatellite instability. Our analysis provides a comprehensive resource of cancer dependencies, a framework to prioritise oncology targets, and nominates specific new candidates. The principles described in this study can transform the initial stages of the drug development process contributing to a new, diverse and more effective portfolio of oncology targets.

Related Papers

• → Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field(2017)52 cited
• → Cas9 Cuts and Consequences; Detecting, Predicting, and Mitigating CRISPR/Cas9 On‐ and Off‐Target Damage(2020)20 cited
• → [Research progress of CRISPR-Cas9 system for gene therapy].(2016)6 cited
• → Prediction of off-target effects of the CRISPR/Cas9 system for design of sgRNA(2020)
• → The CRISPR/Cas9 system forms a condensate in the yeast nucleus(2023)